Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
CRISPR Therapeutics Analyst Ratings and Price Targets | NASDAQ:CRSP | Benzinga
CRISPR Therapeutics AG has a consensus price target of $71.63 based on the ratings of 27 analysts. The high is $120 issued by Truist Securities on February 12, 2025. The low is $30 issued by TD Cowen on December 11, 2023. The 3 most-recent analyst ratings were released by JMP Securities, Needham, and HC Wainwright & Co. on May 21, 2025, May 20, 2025, and May 20, 2025, respectively. With an average price target of $77.33 between JMP Securities, Needham, and HC Wainwright & Co., there's an implied 86.75% upside for CRISPR Therapeutics AG from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Needham
HC Wainwright & Co.
Barclays
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for CRISPR Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/21/2025 | Buy Now | 107.68% | JMP Securities | Silvan Tuerkcan48% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/20/2025 | Buy Now | 95.6% | Needham | Gil Blum53% | $81 → $81 | Reiterates | Buy → Buy | Get Alert |
| 05/20/2025 | Buy Now | 56.97% | HC Wainwright & Co. | Mitchell Kapoor46% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2025 | Buy Now | 1.42% | Barclays | Gena Wang52% | $56 → $42 | Maintains | Equal-Weight | Get Alert |
| 05/08/2025 | Buy Now | 13.5% | Goldman Sachs | Salveen Richter52% | $53 → $47 | Maintains | Neutral | Get Alert |
| 05/07/2025 | Buy Now | 95.6% | Needham | Gil Blum53% | $84 → $81 | Maintains | Buy | Get Alert |
| 05/07/2025 | Buy Now | 98.02% | Chardan Capital | Geulah Livshits50% | $84 → $82 | Maintains | Buy | Get Alert |
| 04/09/2025 | Buy Now | 102.85% | Needham | Gil Blum53% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt35% | — | Reiterates | Neutral → Neutral | Get Alert |
| 02/18/2025 | Buy Now | 98.02% | Citigroup | Yigal Nochomovitz54% | $89 → $82 | Maintains | Buy | Get Alert |
| 02/14/2025 | Buy Now | -22.72% | Morgan Stanley | Terence Flynn66% | $30 → $32 | Maintains | Underweight | Get Alert |
| 02/14/2025 | Buy Now | 139.07% | Evercore ISI Group | Liisa Bayko70% | $60 → $99 | Upgrade | In-Line → Outperform | Get Alert |
| 02/13/2025 | Buy Now | 37.65% | Goldman Sachs | Salveen Richter52% | $66 → $57 | Maintains | Neutral | Get Alert |
| 02/13/2025 | Buy Now | 107.68% | JMP Securities | Silvan Tuerkcan48% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2025 | Buy Now | 18.33% | Stifel | Benjamin Burnett45% | $53 → $49 | Maintains | Hold | Get Alert |
| 02/13/2025 | Buy Now | 56.97% | HC Wainwright & Co. | Mitchell Kapoor46% | $65 → $65 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 102.85% | Chardan Capital | Geulah Livshits50% | $94 → $84 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 189.79% | Truist Securities | Joon Lee77% | $100 → $120 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | 15.91% | RBC Capital | Luca Issi46% | $53 → $48 | Maintains | Sector Perform | Get Alert |
| 02/12/2025 | Buy Now | 102.85% | Needham | Gil Blum53% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 02/12/2025 | Buy Now | 35.23% | Barclays | Gena Wang52% | $55 → $56 | Maintains | Equal-Weight | Get Alert |
| 02/03/2025 | Buy Now | 56.97% | HC Wainwright & Co. | Mitchell Kapoor46% | → $65 | Initiates | → Buy | Get Alert |
| 01/14/2025 | Buy Now | 102.85% | Needham | Gil Blum53% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 01/07/2025 | Buy Now | 105.26% | B of A Securities | Geoff Meacham62% | $98 → $85 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | 107.68% | JMP Securities | Silvan Tuerkcan48% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/10/2024 | Buy Now | 127% | Chardan Capital | Geulah Livshits50% | $94 → $94 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 27.99% | RBC Capital | Luca Issi46% | $53 → $53 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 32.82% | Barclays | Gena Wang52% | $59 → $55 | Maintains | Equal-Weight | Get Alert |
| 11/06/2024 | Buy Now | 102.85% | Needham | Gil Blum53% | $84 → $84 | Reiterates | Buy → Buy | Get Alert |
| 10/04/2024 | Buy Now | 27.99% | RBC Capital | Luca Issi46% | $60 → $53 | Maintains | Sector Perform | Get Alert |
| 08/12/2024 | Buy Now | 141.49% | Truist Securities | Joon Lee77% | $120 → $100 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt35% | — | Reiterates | → Neutral | Get Alert |
| 08/06/2024 | Buy Now | 42.48% | Stifel | Benjamin Burnett45% | $60 → $59 | Maintains | Hold | Get Alert |
| 08/06/2024 | Buy Now | 42.48% | Barclays | Gena Wang52% | $67 → $59 | Maintains | Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | 44.89% | RBC Capital | Luca Issi46% | $66 → $60 | Maintains | Sector Perform | Get Alert |
| 08/06/2024 | Buy Now | 127% | Chardan Capital | Geulah Livshits50% | $112 → $94 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | 102.85% | Needham | Gil Blum53% | $88 → $84 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | — | Guggenheim | Debjit Chattopadhyay56% | — | Assumes | → Neutral | Get Alert |
| 06/27/2024 | Buy Now | 112.51% | Needham | Gil Blum53% | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 153.56% | Piper Sandler | Edward Tenthoff52% | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 112.51% | Needham | Gil Blum53% | $88 → $88 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 102.85% | Citigroup | Yigal Nochomovitz54% | $89 → $84 | Maintains | Buy | Get Alert |
| 05/10/2024 | Buy Now | 129.41% | Oppenheimer | Jay Olson60% | $102 → $95 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | 107.68% | JMP Securities | Silvan Tuerkcan48% | $86 → $86 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/09/2024 | Buy Now | 56.97% | Wells Fargo | Yanan Zhu44% | $70 → $65 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt35% | — | Reiterates | → Neutral | Get Alert |
| 05/09/2024 | Buy Now | 61.8% | Barclays | Gena Wang52% | $80 → $67 | Maintains | Equal-Weight | Get Alert |
| 05/09/2024 | Buy Now | 112.51% | Needham | Gil Blum53% | $90 → $88 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 25.57% | Baird | Jack Allen 38% | $46 → $52 | Maintains | Neutral | Get Alert |
| 04/18/2024 | Buy Now | 114.92% | Citigroup | Yigal Nochomovitz54% | $88 → $89 | Maintains | Buy | Get Alert |
| 04/11/2024 | Buy Now | 117.34% | Needham | Gil Blum53% | $90 → $90 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 139.07% | Mizuho | Salim Syed45% | $82 → $99 | Maintains | Buy | Get Alert |
| 02/26/2024 | Buy Now | 15.91% | Morgan Stanley | Terence Flynn66% | $46 → $48 | Maintains | Underweight | Get Alert |
| 02/22/2024 | Buy Now | 59.38% | RBC Capital | Luca Issi46% | $57 → $66 | Maintains | Sector Perform | Get Alert |
| 02/22/2024 | Buy Now | 69.04% | Wells Fargo | Jim Birchenough60% | $55 → $70 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 93.19% | Barclays | Gena Wang52% | $61 → $80 | Maintains | Equal-Weight | Get Alert |
| 02/22/2024 | Buy Now | 170.47% | Chardan Capital | Geulah Livshits50% | $110 → $112 | Maintains | Buy | Get Alert |
| 02/21/2024 | Buy Now | 117.34% | Needham | Gil Blum53% | $88 → $90 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen48% | — | Initiates | → Peer Perform | Get Alert |
| 12/11/2023 | Buy Now | 37.65% | RBC Capital | Luca Issi46% | $50 → $57 | Maintains | Sector Perform | Get Alert |
| 12/11/2023 | Buy Now | 286.38% | Truist Securities | Joon Lee77% | $220 → $160 | Maintains | Buy | Get Alert |
| 12/11/2023 | Buy Now | 47.31% | Barclays | Gena Wang52% | $56 → $61 | Maintains | Equal-Weight | Get Alert |
| 12/11/2023 | Buy Now | -27.55% | TD Cowen | Tyler Van Buren46% | → $30 | Downgrade | Market Perform → Underperform | Get Alert |
| 12/11/2023 | Buy Now | 93.19% | JMP Securities | Silvan Tuerkcan48% | $74 → $80 | Maintains | Market Outperform | Get Alert |
| 12/11/2023 | Buy Now | 112.51% | Needham | Gil Blum53% | $85 → $88 | Maintains | Buy | Get Alert |
| 12/08/2023 | Buy Now | 431.27% | Truist Securities | Joon Lee77% | → $220 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | Buy Now | 98.02% | Mizuho | Salim Syed45% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2023 | Buy Now | 78.7% | JMP Securities | Silvan Tuerkcan48% | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/13/2023 | Buy Now | 1.42% | Morgan Stanley | Terence Flynn66% | $43 → $42 | Maintains | Underweight | Get Alert |
| 11/07/2023 | Buy Now | 20.74% | RBC Capital | Luca Issi46% | $55 → $50 | Maintains | Sector Perform | Get Alert |
| 11/07/2023 | Buy Now | 105.26% | Needham | Gil Blum53% | $88 → $85 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | 112.51% | Needham | Gil Blum53% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | Buy Now | 112.51% | Needham | Gil Blum53% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 10/17/2023 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt35% | — | Downgrade | Overweight → Neutral | Get Alert |
| 09/27/2023 | Buy Now | 98.02% | Mizuho | Salim Syed45% | → $82 | Initiates | → Buy | Get Alert |
| 08/18/2023 | Buy Now | 69.04% | Citigroup | Yigal Nochomovitz54% | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/17/2023 | Buy Now | 69.04% | Citigroup | Yigal Nochomovitz54% | → $70 | Upgrade | Neutral → Buy | Get Alert |
| 08/14/2023 | Buy Now | 3.84% | Morgan Stanley | Terence Flynn66% | $42 → $43 | Maintains | Underweight | Get Alert |
| 08/10/2023 | Buy Now | 146.32% | Oppenheimer | Jay Olson60% | → $102 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 52.14% | Credit Suisse | Richard Law48% | $62 → $63 | Maintains | Neutral | Get Alert |
| 08/08/2023 | Buy Now | 81.12% | EF Hutton | Tony Butler42% | → $75 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 112.51% | Needham | Gil Blum53% | → $88 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 165.64% | Chardan Capital | Geulah Livshits50% | $123 → $110 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | 78.7% | JMP Securities | Silvan Tuerkcan48% | → $74 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | 112.51% | Needham | Gil Blum53% | $82 → $88 | Reiterates | Buy → Buy | Get Alert |
| 06/09/2023 | Buy Now | 78.7% | JMP Securities | Silvan Tuerkcan48% | $70 → $74 | Maintains | Market Outperform | Get Alert |
| 06/09/2023 | Buy Now | 81.12% | EF Hutton | Tony Butler42% | → $75 | Reiterates | → Buy | Get Alert |
| 06/01/2023 | Buy Now | 54.55% | Barclays | Gena Wang52% | $61 → $64 | Maintains | Equal-Weight | Get Alert |
| 05/30/2023 | Buy Now | 81.12% | William Blair | Sami Corwin18% | → $75 | Reinstates | → Outperform | Get Alert |
| 05/23/2023 | Buy Now | 69.04% | Citigroup | Yigal Nochomovitz54% | $55 → $70 | Maintains | Neutral | Get Alert |
| 05/12/2023 | Buy Now | 1.42% | Morgan Stanley | Terence Flynn66% | $39 → $42 | Maintains | Underweight | Get Alert |
| 05/09/2023 | Buy Now | 20.74% | RBC Capital | Luca Issi46% | → $50 | Reiterates | → Sector Perform | Get Alert |
| 05/09/2023 | Buy Now | 69.04% | JMP Securities | Silvan Tuerkcan48% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 05/09/2023 | Buy Now | 49.72% | Credit Suisse | Richard Law48% | $65 → $62 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | 54.55% | Stifel | Benjamin Burnett45% | $69 → $64 | Maintains | Hold | Get Alert |
| 05/09/2023 | Buy Now | 98.02% | Needham | Gil Blum53% | → $82 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | Buy Now | 98.02% | Needham | Gil Blum53% | → $82 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 69.04% | JMP Securities | Silvan Tuerkcan48% | → $70 | Reiterates | → Market Outperform | Get Alert |
| 04/17/2023 | Buy Now | 81.12% | EF Hutton | Tony Butler42% | → $75 | Reiterates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 73.87% | Cantor Fitzgerald | Olivia Brayer53% | → $72 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for CRISPR Therapeutics (CRSP) stock?
The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by JMP Securities on May 21, 2025. The analyst firm set a price target for $86.00 expecting CRSP to rise to within 12 months (a possible 104.71% upside). 41 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CRISPR Therapeutics (CRSP)?
The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by JMP Securities, and CRISPR Therapeutics reiterated their market outperform rating.
When was the last upgrade for CRISPR Therapeutics (CRSP)?
The last upgrade for CRISPR Therapeutics AG happened on February 14, 2025 when Evercore ISI Group raised their price target to $99. Evercore ISI Group previously had an in-line for CRISPR Therapeutics AG.
When was the last downgrade for CRISPR Therapeutics (CRSP)?
The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.
When is the next analyst rating going to be posted or updated for CRISPR Therapeutics (CRSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on May 21, 2025 so you should expect the next rating to be made available sometime around May 21, 2026.
Is the Analyst Rating CRISPR Therapeutics (CRSP) correct?
While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a reiterated with a price target of $86.00 to $86.00. The current price CRISPR Therapeutics (CRSP) is trading at is $42.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
